FACULTAD DE MEDICINA HUMANA Y

CIENCIAS DE LA SALUD
ESCUELA ACADEMICA PROFESIONAL
DE MEDICINA HUMANA

FOP

FIBRODYSPLASIA OSSIFICANS
PROGRESSIVA
SUBJECT : INTERMEDIATE ENGLISH II
PROFFESOR : LIC.JANETH LPEZ MEJA
STUDENT : CRUZ YUFRA GERALDINE

INTRODUCTION:
The worldwide
prevalence is
approximately

1 / 2,
000,000
700 cases described
in the investigations ,
but only 200 are
registered.

The median lifespan is

approximately 40 years of age.

WHAT IS FIBRODYSPLASIA
OSSIFICANS PROGRESSIVA (FOP)?

Muscle
tissue
Connective
tissue:
Tendons
Ligaments

Starting with the

neck and shoulders
and proceeding
down the body and
into the limbs.

WHAT CAUSES FIBRODYSPLASIA

OSSIFICANS PROGRESSIVA (FOP)?

Autosomal
Dominant
Condition but most
often sporadic.

Mutations on the
ACVR1 gene
(activin A receptor,
Type I)

Cytogenetic Location: 2q23q24

The ACVR1 protein

WHAT ARE THE SIGNS AND SYMPTOMS OF

FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)?

BIG TOE IS SHORT

OSSIFICATION OF TENDONS AND

MUSCLES

THE FORMATION OF TUMOR-LIKE

LUMPS IN THE AFFECTED REGIONS.

HOW IS FIBRODYSPLASIA
OSSIFICANS PROGRESSIVA
(FOP) DIAGNOSED?

HOW IS FIBRODYSPLASIA OSSIFICANS

PROGRESSIVA (FOP) TREATED?

Treatment and
lifestyle
changes may
help reduce
symptoms

E
R
U
NO C

NONSTEROIDAL ANTIINFLAMMATORY
DRUGS

HOW CAN FIBRODYSPLASIA OSSIFICANS

PROGRESSIVA (FOP) BE PREVENTED?

Good oral
hygiene
People with FOP should
avoid wearing tight
clothing
Avoid unnecessary
intramuscular injections

Minimize the risk of traumatic

injuries

CASE STUDY

A 10-YEAR-OLD
FEMALE PATIENT

PROGRESSIVE STIFFNESS OF
THE JOINTS AND SPINE AND
OSSIFICATION OF SOFT
TISSUES

PHYSICAL EXAMINATION

CONCLUSION

E
R
U
NO C

NONSTEROIDAL ANTIINFLAMMATORY
DRUGS